18F-Fluciclovine PET/CT in Multiple Myeloma | MicrobiomeTrials← Back to trialsNCT06103838
18F-Fluciclovine PET/CT in Multiple Myeloma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-03-25Est. Completion: 2027-12-06
Enrollment target: 60 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Multiple Myeloma
Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myel…
Daphne, United StatesEst. completion Oct 18, 2030
Newly Diagnosed Multiple Myeloma (NDMM)
The goal of this clinical trial is to evaluate whether a modified (less frequent) dosing schedule of daratumumab, when a…
Navi Mumbai, IndiaEst. completion May 5, 2029
Phase 2
Recruiting
Multiple Myeloma, Newly Diagnosed
This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of autologous stem cell transplant…
Tianjin, ChinaEst. completion Aug 1, 2027